Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has shared an announcement.
Onco-Innovations Limited has announced the advancement of its PNKP Inhibitor Technology through a partnership with Dalton Pharma Services, focusing on process optimization and scale-up activities for future Phase 1 clinical studies. This development marks a significant step from lab-scale synthesis to scalable pre-clinical manufacturing, aiming to enhance tumor-targeted delivery and improve therapeutic efficacy in cancer treatment. The work involves refining the synthesis process, conducting analytical method development, and ensuring compliance with international quality standards, setting the stage for future GMP production and clinical trial readiness.
More about Onco-Innovations Ltd.
Onco-Innovations is a Canadian-based company specializing in oncology, dedicated to cancer research and treatment. The company focuses on pioneering research and innovative solutions for the prevention and treatment of cancer, holding an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 36,361
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$79.79M
See more insights into ONCO stock on TipRanks’ Stock Analysis page.